These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 7059438)

  • 61. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.
    Boobis AR; Brodie MJ; Kahn GC; Toverud EL; Blair IA; Murray S; Davies DS
    Br J Clin Pharmacol; 1981 Dec; 12(6):771-7. PubMed ID: 7340879
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.
    Bax ND; Lennard MS; Tucker GT
    Br J Clin Pharmacol; 1981 Dec; 12(6):779-84. PubMed ID: 6122461
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antipyrine clearance and metabolite formation in primary biliary cirrhosis.
    Jorquera F; Almar M; Linares A; Olcóz JL; Rodrigo L; González-Gallego J
    Dig Dis Sci; 2001 Feb; 46(2):352-9. PubMed ID: 11281185
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The effect of age on antipyrine pharmacokinetics and metabolite formation in rats.
    van Bezooijen CF; van Oorschot RM
    J Pharmacol Exp Ther; 1989 Nov; 251(2):683-6. PubMed ID: 2810117
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differential induction of cytochrome P450 isoforms and peroxisomal proliferation by cyfluthrin in male Wistar rats.
    Anadón A; Martínez MA; Martínez M; Castellano V; Ares I; Romero A; Fernández R; Martínez-Larrañaga MR
    Toxicol Lett; 2013 Jul; 220(2):135-42. PubMed ID: 23639246
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of flumethrin on hepatic drug-metabolizing enzymes and antipyrine disposition in rats.
    Anadón A; Martinez-Larrañaga MR; Diaz MJ; Bringas P; Fernandez MC; Martinez MA; Fernandez-Cruz ML
    Toxicol Appl Pharmacol; 1995 May; 132(1):14-8. PubMed ID: 7747277
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Influence of sex and oral contraceptive steroids on antipyrine metabolite formation.
    Teunissen MW; Srivastava AK; Breimer DD
    Clin Pharmacol Ther; 1982 Aug; 32(2):240-6. PubMed ID: 7094512
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of phenobarbital and spironolactone treatment on the oxidative metabolism of antipyrine by rat liver microsomes.
    Szakács T; Veres Z; Vereczkey L
    Pol J Pharmacol; 2001; 53(1):11-9. PubMed ID: 11785906
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.
    Sakai H; Kobayashi S; Hamada K; Iida S; Akita H; Tanaka E; Uchida E; Yasuhara H
    Br J Clin Pharmacol; 1991 Mar; 31(3):353-5. PubMed ID: 2054276
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antipyrine elimination and hepatic microsomal enzyme activity in patients with liver disease.
    Wensing G; Ohnhaus EE; Hoensch HP
    Clin Pharmacol Ther; 1990 Jun; 47(6):698-705. PubMed ID: 2113450
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effect of malaria infection on antipyrine metabolite formation in the rat.
    Mansor SM; Ward SA; Edwards G
    Biochem Pharmacol; 1991 Apr; 41(8):1264-6. PubMed ID: 2009102
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.
    Perucca E; Grimaldi R; Frigo GM; Sardi A; Mönig H; Ohnhaus EE
    Eur J Clin Pharmacol; 1988; 34(6):595-9. PubMed ID: 2901960
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.
    Eichelbaum M; Ochs HR; Roberts G; Somogyi A
    Arzneimittelforschung; 1982; 32(5):575-8. PubMed ID: 7201837
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antipyrine metabolism in the Venda.
    Sommers DK; Moncrieff J; Avenant JC
    Hum Toxicol; 1987 Mar; 6(2):127-31. PubMed ID: 3557469
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
    Wensing G; Hoffmann K; Heidemann HT
    Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine.
    Breimer DD; Zilly W; Richter E
    Clin Pharmacol Ther; 1977 Apr; 21(4):470-81. PubMed ID: 849678
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative.
    Vital Durand D; Hampden C; Boobis AR; Park BK; Davies DS
    Br J Clin Pharmacol; 1986 Jan; 21(1):1-7. PubMed ID: 3947503
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.
    Schellens JH; van der Wart JH; Danhof M; van der Velde EA; Breimer DD
    Br J Clin Pharmacol; 1988 Oct; 26(4):373-84. PubMed ID: 3190987
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The effect of sex on antipyrine metabolism in cattle at different ages.
    Janus K; Antoszek J
    J Vet Pharmacol Ther; 1999 Jun; 22(3):163-9. PubMed ID: 10447826
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The influence of aging on the metabolism of simultaneously administered hexobarbital enantiomers and antipyrine before and after phenobarbital induction in male rats: a longitudinal study.
    Groen K; Breimer DD; Jansen EJ; van Bezooijen CF
    J Pharmacol Exp Ther; 1994 Feb; 268(2):531-6. PubMed ID: 8113964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.